Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of "Hold" by Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) has earned an average rating of "Hold" from the twenty-two brokerages that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $113.45.

A number of equities analysts have commented on ZBH shares. JMP Securities reduced their target price on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Royal Bank of Canada cut their price objective on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Raymond James cut their price target on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Wells Fargo & Company reduced their price objective on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Finally, Truist Financial set a $101.00 target price on shares of Zimmer Biomet in a research report on Tuesday, May 6th.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.39% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors have recently modified their holdings of the stock. Stonebridge Financial Group LLC bought a new stake in Zimmer Biomet in the fourth quarter valued at about $25,000. Garde Capital Inc. bought a new stake in shares of Zimmer Biomet in the 1st quarter valued at approximately $29,000. Menard Financial Group LLC acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at approximately $30,000. Washington Trust Advisors Inc. bought a new position in Zimmer Biomet during the first quarter worth $30,000. Finally, Columbia River Financial Group LLC acquired a new position in Zimmer Biomet in the first quarter worth $30,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

NYSE ZBH traded up $2.97 on Friday, reaching $98.18. The stock had a trading volume of 3,166,338 shares, compared to its average volume of 1,728,035. The stock has a market cap of $19.42 billion, a P/E ratio of 22.06, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. Zimmer Biomet has a 12-month low of $89.92 and a 12-month high of $122.25. The business's 50-day moving average price is $104.30 and its 200 day moving average price is $106.10. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm's revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.94 EPS. As a group, equities analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet's payout ratio is 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.